All In Biotech

NDA 214701 · Blueprint Medicines

Gavreto

Pralsetinib · Oral

Breakthrough therapyAccelerated approvalPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Dec 1, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Dec 1, 2020

Approved uses

1

Original approval plus efficacy supplements

Registered trials

14

2 Phase 3, 6 recruiting

FAERS reports

1,824

1,139 serious, 259 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 1, 2020 Original approval · Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval · priority review Breakthrough therapyAccelerated approvalOrphanLabelLetterReview
1 products under this application
  • GAVRETO · PRALSETINIB 100MG · CAPSULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Pralsetinib" as an intervention, any sponsor and status, largest first.

All 14 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • product prescribing issue194
  • death152
  • fatigue126
  • off label use120
  • asthenia117
  • anaemia99
  • diarrhoea96
  • hypertension96
  • disease progression91
  • blood pressure increased90
  • constipation90
  • white blood cell count decreased85

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202048
2021467
2022275
2023179
2024370
2025323
2026162

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Gavreto (Pralsetinib)

2024 spending

$14.9M

Beneficiaries

159

980 claims

Per beneficiary

$93,739

$182.00 per unit

View as table
YearSpending
2020$0
2021$2,558,955
2022$8,399,605
2023$11,030,094
2024$14,904,520

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 10 on PubMed

Sponsor: Blueprint Medicines

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.